ZSTK · ZeroStack Corp.

The options were approved by the Issuer's board of directors on March 5, 2026, subject to shareholder approval, which occurred on July 20, 2026. The options vest in five equal installments; the vesting of each 20% installment is contingent on the Issuer's volume weighted average price reaching a specified threshold.

Purchase price in the form of native blockchain tokens; each token deemed to have a value of US$0.7549.

Held by Zero Gravity Labs Inc., a Delaware corporation owned and controlled by the Reporting Person.

The warrants were not exercisable until approved by the Issuer's shareholders and terminated upon full exercise of the warrants

The options were approved by the Issuer's board of directors on March 5, 2026, subject to shareholder approval, which occurred on July 20, 2026. The options vest in five equal installments; the vesting of each 20% installment is contingent on the Issuer's volume weighted average price reaching a specified threshold.

The options were approved by the Issuer's board of directors on March 5, 2026, subject to shareholder approval, which occurred on July 20, 2026. The options vest in five equal installments; the vesting of each 20% installment is contingent on the Issuer's volume weighted average price reaching a specified threshold.

The options vest as follows: 1/3 on May 5, 2026; 1/3 on August 30, 2026; and 1/3 on December 31, 2026.

The options vest as follows: 1/3 on May 5, 2026; 1/3 on August 30, 2026; 1/3 on December 31, 2026.

The options vest as follows: 1/3 on May 5, 2026; 1/3 on August 30, 2026; and 1/3 on December 31, 2026.

On March 31, 2026, the Issuer entered into a note settlement agreement (the "Note Settlement Agreement") with Zero Gravity Labs Inc., a Delaware corporation ("0G") pursuant to which the convertible promissory note (the "Note") issued to 0G pursuant to the securities purchase agreement dated September 22, 2025, as amended on October 9, 2025, by and between the Issuer and 0G was settled. The Note Settlement Agreement provides that upon payment by the Issuer to 0G on or before March 31, 2026, of 50,000,000 Tokens (as defined in the Note), the Issuer shall be deemed to have paid the entire Principal (as defined in the Note) and Interest (as defined in the Note) of the Note in full and the Issuer shall have no further obligations under the Note and the Note shall be deemed to be satisfied.

Represents issuance of convertible promissory note to Zero Gravity Labs Inc., a Delaware corporation owned and controlled by the Reporting Person, in the principal amount of 50,000,000 0G bitcoin tokens.

The options vest in five equal installments; the vesting of each 20% installment is contingent on the Issuer's volume weighted average price reaching a specified threshold.

The options vest in five equal installments; the vesting of each 20% installment is contingent on the Issuer's volume weighted average price reaching a specified threshold.

The options vest in five equal installments; the vesting of each 20% installment is contingent on the Issuer's volume weighted average price reaching a specified threshold.

Represents issuance of convertible promissory note to Zero Gravity Labs Inc., a Delaware corporation owned and controlled by the Reporting Person, in the principal amount of 50,000,000 OG bitcoin tokens. Subject to shareholder approval, which occurred on October 22, 2025, the entire outstanding amount of principal and interest may be converted, at the option of the Holder, into common shares of the Issuer. The total number of common shares reported on this Form 4 includes 4,499,100 common shares underlying the principal amount of the convertible note, plus 403,120 common shares underlying interest on the convertible note through September 2026.

Each DSU represents the right to receive one common share of the Issuer. The underlying common shares will not be issued to the Reporting Person, and the Reporting Person shall not have any voting or dispositive rights with respect to the underlying common shares, until termination of the Reporting Person's employment or services as a director of the Issuer. Grants to U.S. eligible participants will be settled with no further action by the Reporting Person on the date that is 6 months following the Reporting Person's termination date. Grants to non-U.S. eligible participants will be settled with no further action by the Reporting Person on the 20th business day following the Reporting Person's termination date.

The warrants are not exercisable until approved by the Issuer's shareholders and terminate upon full exercise of the warrants.

The SARs granted to the reporting person on December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs granted to the reporting person on December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs granted to the reporting person on December 15, 2023, August 14, 2024, and December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs granted to the reporting person on December 15, 2023, August 14, 2024, and December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 8 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

The SARs granted to the reporting person on December 15, 2023, and August 14, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 9 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

The SARs granted to the reporting person on December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs granted to the reporting person on December 15, 2023, August 14, 2024, and December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 8 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

The SARs granted to the reporting person on December 15, 2023, August 14, 2024, and December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 8 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

The SARs granted to the reporting person on December 15, 2023, August 14, 2024, and December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs granted to the reporting person on December 15, 2023, and August 14, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 9 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

The SARs granted to the reporting person on December 15, 2023, and August 14, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 9 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

The SARs granted to the reporting person on December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs granted to the reporting person on December 15, 2023, and August 14, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 9 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

The SARs granted to the reporting person on December 15, 2023, August 14, 2024, and December 15, 2024, were amended, with shareholder approval, to have a lower exercise price.

The SARs vest in 8 equal installments, subject to stock price criteria to be met prior to each trance vesting. The SARs have a post-termination exercise period of one year.

Represents grant of restricted shares which vest on December 15, 2024.

Represents grant of restricted shares which vest on December 15, 2024.

Represents grant of restricted shares which vest on December 15, 2024.

473,995 common shares previously held directly by the Reporting Person have been transferred to YT Research, Inc., a company in which the Reporting Person is the sole director and equity owner.

The SARs vest in 12 equal installments, subject to stock price criteria to be met prior to each tranche vesting. The SARs have a post-termination exercise period of one year.

The SARs vest in 12 equal installments, subject to stock price criteria to be met prior to each tranche vesting. The SARs have a post-termination exercise period of one year.